International Journal of Particle Therapy

11/02/2026

Accurate target localization across imaging and treatment platforms remains a challenge in modern radiotherapy.

A new study in the International Journal of Particle Therapy explores the development and performance of universal fiducial markers designed for seamless use across CT, MRI, and particle therapy workflows.

This work highlights how standardized fiducials could:

✅ Improve localization accuracy and consistency
✅ Reduce workflow complexity and inter-platform variability
✅ Streamline clinical operations across multi-modal environments
✅ Support broader adoption of advanced radiotherapy techniques

🔗 Read the full article: https://www.sciencedirect.com/science/article/pii/S2331518026000119

29/01/2026

Particle therapy has a long and distinguished track record in the treatment of ocular tumors. Since 1975, nearly 50,000 patients worldwide have been treated with protons and light ions, demonstrating the clinical value of this specialized modality.

Now in press with the International Journal of Particle Therapy: results from a PTCOG Ocular Subcommittee global survey that capture the latest worldwide trends, techniques, and clinical practices in ocular particle therapy.

🔗 Read the study: https://www.sciencedirect.com/science/article/pii/S233151802600003X

14/01/2026

“For a moment, protons felt like a near-universal answer for complex GI cancers. But early awe gradually evolved into a deeper appreciation of the truth: proton therapy is not simply a sharper version of photons. It is a fundamentally different modality—one that demands new thinking, new workflows, and a new level of vigilance.”

Read about Dr. Ashu Abhishek’s transition from photon-based radiotherapy to proton therapy for gastrointestinal cancers at the Apollo Proton Cancer Centre online with IJPT now: https://www.sciencedirect.com/science/article/pii/S2331518026000028

08/01/2026

Adenoid cystic carcinoma of the head and neck is a rare malignancy with a high risk of perineural invasion, local recurrence, and distant metastasis and poses unique challenges due to its aggressive nature, resection limited by morbidity, and prior radiation.

Proton therapy, with its ability to spare normal tissues via the Bragg peak, may offer a promising and safe re-irradiation approach, especially in patients not amenable to resection requiring high definitive doses.

Read a study in press now with IJPT that evaluates outcomes of patients with recurrent adenoid cystic carcinoma treated with proton radiation: https://www.sciencedirect.com/science/article/pii/S233151802500561X

01/01/2026

Classical Hodgkin lymphoma is associated with favorable prognosis and high overall survival. Consolidative proton therapy represents a modality recommended for young patients due to its reduction in exit dose, with a goal to minimize late effects.

Start off the New Year with an important study presenting outcomes of pediatric patients with classical Hodgkin lymphoma receiving consolidative proton therapy: https://www.sciencedirect.com/science/article/pii/S2331518025005608

15/12/2025

15/12/2025

Only 1 month left to submit your abstract for !

Share your research & innovations in particle therapy before 13 Jan 2026!!

🔗 Learn more here:

PTCOG 64 – Join us from 8-13 June 2026 in Deauville, Normandy, France. Discover the latest research, innovations, and clinical advancements in particle therapy.

11/12/2025

IJPT Vol.18 is now online!

Read about advances in proton & carbon-ion therapy across clinical, technical and biological fronts: improved target coverage for pancreatic cancer, proton reirradiation for lung, RBE practice, automated QA/planning, treatment-time benchmarks, and radiobiology insights - https://www.sciencedirect.com/journal/international-journal-of-particle-therapy/vol/18/suppl/C

21/11/2025

Rates of local regional recurrence and secondary metachronous thoracic tumors remain high for patients with inoperable early and locally advanced non-small cell lung cancer treated with prior radiation.

These clinical situations pose therapeutic challenges due to the potential added toxicity of reirradiation.

During Lung Cancer Awareness Month, we are pleased to present a study demonstrating the feasibility and efficacy of a hypofractionated course of proton reirradiation for recurrent thoracic tumors - in press with IJPT now: https://www.sciencedirect.com/science/article/pii/S2331518025004780

14/11/2025

Developing consensus guidelines and integrating advanced relative biological effectiveness (RBE) and LET-based models into treatment planning could improve precision and safety of proton therapy.

Read the results of an important survey of 29 U.S. proton therapy centers assessing awareness and management of RBE variability in clinical practice: https://www.sciencedirect.com/science/article/pii/S2331518025004779

12/11/2025

Our first AI in Particle Therapy Special Issue article is available!

Radiotherapy can lead to radiation-induced optic neuropathy, with vision loss and visual field deficits related to damage to the optic pathways: Accurately quantifying visual field deficits and establishing their spatial relationship with anatomical structures and radiation dose distribution remains a significant challenge.

Learn how researchers from Université de Caen- Normandie; Centre François Baclesse; and Hôpital de La Croix-Rousse, Hospices Civils de Lyon applied a novel artificial intelligence approach in oncology to identify patterns of visual field loss and model their spatial evolution over time after pencil beam scanning proton therapy: https://www.sciencedirect.com/special-issue/10J8TL0GQ4D